Orgenesis Statistics
Total Valuation
Orgenesis has a market cap or net worth of $17.38 million. The enterprise value is $38.52 million.
| Market Cap | 17.38M |
| Enterprise Value | 38.52M |
Important Dates
The next estimated earnings date is Wednesday, May 8, 2024, after market close.
| Earnings Date | May 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Orgenesis has 34.15 million shares outstanding. The number of shares has increased by 15.59% in one year.
| Shares Outstanding | 34.15M |
| Shares Change (YoY) | +15.59% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | 20.99% |
| Owned by Institutions (%) | 6.78% |
| Float | 28.14M |
Valuation Ratios
The trailing PE ratio is 0.27 and the forward PE ratio is 0.94.
| PE Ratio | 0.27 |
| Forward PE | 0.94 |
| PS Ratio | 32.79 |
| Forward PS | 0.26 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 72.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.25
| Current Ratio | 0.25 |
| Quick Ratio | 0.12 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.96 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -178.10% |
| Return on Capital (ROIC) | -3,187.00% |
| Revenue Per Employee | $3,174 |
| Profits Per Employee | -$331,503 |
| Employee Count | 167 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 219.19 |
Taxes
In the past 12 months, Orgenesis has paid $473,000 in taxes.
| Income Tax | 473,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -54.96% in the last 52 weeks. The beta is 1.10, so Orgenesis's price volatility has been similar to the market average.
| Beta (1Y) | 1.10 |
| 52-Week Price Change | -54.96% |
| 50-Day Moving Average | 0.62 |
| 200-Day Moving Average | 0.68 |
| Relative Strength Index (RSI) | 42.00 |
| Average Volume (30 Days) | 248,640 |
Short Selling Information
The latest short interest is 299,687, so 0.88% of the outstanding shares have been sold short.
| Short Interest | 299,687 |
| Short Previous Month | 322,208 |
| Short % of Shares Out | 0.88% |
| Short % of Float | 1.06% |
| Short Ratio (days to cover) | 3.78 |
Income Statement
In the last 12 months, Orgenesis had revenue of $530,000 and -$55.36 million in losses.
| Revenue | 530,000 |
| Gross Profit | -16.35M |
| Operating Income | -52.20M |
| Pretax Income | -54.89M |
| Net Income | -55.36M |
| EBITDA | -50.83M |
| EBIT | -52.39M |
| Earnings Per Share (EPS) | $1.91 |
Balance Sheet
The company has $1.48 million in cash and $22.62 million in debt, giving a net cash position of -$21.14 million or -$0.62 per share.
| Cash & Cash Equivalents | 1.48M |
| Total Debt | 22.62M |
| Net Cash | -21.14M |
| Net Cash Per Share | -$0.62 |
| Equity / Book Value | -20.98M |
| Book Value Per Share | -0.61 |
| Working Capital | -12.33M |
Cash Flow
In the last 12 months, operating cash flow was -$14.84 million and capital expenditures -$2.10 million, giving a free cash flow of -$16.93 million.
| Operating Cash Flow | -14.84M |
| Capital Expenditures | -2.10M |
| Free Cash Flow | -16.93M |
| FCF Per Share | -$0.58 |
Margins
Gross margin is -3,084.53%, with operating and profit margins of -9,849.62% and -10,445.47%.
| Gross Margin | -3,084.53% |
| Operating Margin | -9,849.62% |
| Pretax Margin | -10,356.23% |
| Profit Margin | -10,445.47% |
| EBITDA Margin | -9,590.38% |
| EBIT Margin | -9,884.72% |
| FCF Margin | -3,194.91% |
Dividends & Yields
Orgenesis does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.59% |
| Shareholder Yield | -15.59% |
| Earnings Yield | -318.55% |
| FCF Yield | -97.43% |
Analyst Forecast
The average price target for Orgenesis is $6.00, which is 1,079.01% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 1,079.01% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 16, 2017. It was a reverse split with a ratio of 1:12.
| Last Split Date | Nov 16, 2017 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
Orgenesis has an Altman Z-Score of -29.56 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -29.56 |
| Piotroski F-Score | 1 |